http://rdf.ncbi.nlm.nih.gov/pubchem/patent/RU-2013142012-A
Outgoing Links
| Predicate | Object |
|---|---|
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D513-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-16 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-28 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-554 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P3-10 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D417-12 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D417-12 |
| filingDate | 2012-02-28-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationDate | 2015-04-10-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | RU-2013142012-A |
| titleOfInvention | 1,4 THIAZEPINES / SULPHONES AS BACE1 AND (OR) BACE2 INHIBITORS |
| abstract | 1. The compound of formula I where R is selected from the group consisting of i) hydrogen, ii) halogen and iii) C-alkyl; R is selected from the group consisting of i) hydrogen, ii) C-alkyl and iii) halogen-C-alkyl; R is selected from the group consisting of from i) hydrogen and ii) C-alkyl; R is selected from the group consisting of i) hydrogen and ii) C-alkyl; R is heteroaryl, unsubstituted or substituted by one or two substituents individually selected from the group consisting of i) C-alkyl, ii) halogen, iii) C-alkoxy; and iv) halogen-C-alkyl, R is hydrogen; R is hydrogen; R is hydrogen od; R 1 represents hydrogen; or R and R together form a 5-6 membered heterocyclyl, X is selected from the group consisting of i) -S and ii) -SO; or its pharmaceutically acceptable salts. 2. A compound of formula I, wherein R is selected from the group consisting of i) hydrogen, ii) halogen and iii) C-alkyl; R is selected from the group consisting of i) hydrogen, ii) C-alkyl and iii) halogen-C-alkyl; R is selected from the group consisting of i) hydrogen and ii) C-alkyl; R is selected from the group consisting of i) hydrogen and ii) C-alkyl; R is heteroaryl, unsubstituted or substituted by one or two substituents individually selected from the group consisting of i) C-alkyl, ii ) halogen, iii) C-alkoxy, and iv) halogen-C-alkyl, X is selected from the group consisting of i) -S and ii) -SO; or pharmaceutically acceptable salts thereof. 3. A compound of formula Ia according to any one of claims 1 or 2, wherein R is selected from the group consisting of i) hydrogen, ii) halogen and iii) C-alkyl; R is selected from the group consisting of i) hydrogen, ii) C-alkyl and iii) halogen -C-alkyl; R is selected from the group consisting of i) hydrogen and ii) C-alkyl; R is selected from the group consisting of i) hydrogen and ii) C-alkyl; R is heteroaryl, unsubstituted or substituted by one or two substituents, and |
| priorityDate | 2011-03-04-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 42.